The conditional, time-limited approval comes through a joint effort with RACTHERA, a joint venture in which Sumitomo Chemical holds a 66.6% stake and Sumitomo Pharma holds 33.4%
The company will address the observations and respond to the U.S. FDA within the stipulated timeframe
The document, published under the Accelerating Clinical Trials in the EU (ACT EU) initiative, sets out how trials should be conducted when health emergencies disrupt normal research operations
Gazyva/Gazyvaro outperformed placebo across all key and secondary endpoints
Evogene said ChemPass AI was significantly expanded during 2025 through internal development and collaborations with Google Cloud
The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
The company announced positive topline data from the Phase II ZUPREME-1 trial
Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results
Hyderabad emerged as Lonza’s preferred destination after an extensive global evaluation process
Subscribe To Our Newsletter & Stay Updated
